13F-HR filed by SAMSARA BIOCAPITAL, LLC
SAMSARA BIOCAPITAL, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:45:44 UTC, with 27 holding rows worth $1,051,599,250.
- Accession
- 0001744967-26-000014
- Filer
- CIK 1744967
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 27 entries on the cover page, a total value of $1,051,599,250 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,051,599,250 with VALUE read as dollars as filed, 13F file number 028-19375. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| SCHOLAR ROCK HLDG CORP | 80706P103 | COM | 6,897,652 | $333,294,545 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 5,871,018 | $147,538,682 | dollars as filed | |
| SEPTERNA INC COM | 81734D104 | Stock | 3,066,453 | $119,990,306 | dollars as filed | |
| ALAMAR BIOSCIENCES INC | 010911105 | COMMON STOCK | 2,480,310 | $84,504,162 | dollars as filed | |
| SPYGLASS PHARMA INC | 85220G109 | COMMON STOCK | 2,109,953 | $54,858,778 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 7,235,809 | $53,472,629 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 1,867,127 | $51,943,473 | dollars as filed | |
| KALARIS THERAPEUTICS INC | 482929106 | COM | 12,881,175 | $37,226,596 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 6,314,805 | $23,301,630 | dollars as filed | |
| PARABILIS MEDICINES INC COM | 698955101 | Stock | 556,044 | $17,954,661 | dollars as filed | |
| SUTRO BIOPHARMA INC | 869367201 | COMMON STOCK | 1,062,872 | $17,122,868 | dollars as filed | |
| PMV PHARMACEUTICALS INC | 69353Y103 | COM | 7,240,000 | $12,090,800 | dollars as filed | |
| Obsidian Therapeutics, Inc. | 67448A106 | Common Stock, $0.0001 par value per share | 837,173 | $11,494,385 | dollars as filed | |
| AQUESTIVE THERAPEUTICS INC COM | 03843E104 | Stock | 2,434,367 | $11,271,119 | dollars as filed | |
| VTV THERAPEUTICS INC | 918385204 | CL A NEW | 354,730 | $10,939,873 | dollars as filed | |
| JADE BIOSCIENCES INC | 008064206 | COM NEW | 736,237 | $10,344,130 | dollars as filed | |
| NKARTA INC | 65487U108 | COMMON STOCK | 3,507,666 | $9,190,085 | dollars as filed | |
| RANI THERAPEUTICS HLDGS INC | 753018100 | CMN | 10,369,159 | $8,202,005 | dollars as filed | |
| ARTIVA BIOTHERAPEUTICS INC | 04317A107 | COM | 954,861 | $6,798,610 | dollars as filed | |
| AGOMAB THERAPEUTICS NV | 00860C102 | SPONSORED ADS | 594,749 | $6,601,714 | dollars as filed | |
| ELOXX PHARMACEUTICALS INC | 29014R301 | COM NEW | 400,000 | $6,124,000 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 55,095 | $5,455,507 | dollars as filed | |
| COHERUS ONCOLOGY INC | 19249H103 | COM | 3,383,565 | $4,094,114 | dollars as filed | |
| X4 PHARMACEUTICALS INC | 98420X202 | COMMON STOCK | 1,347,723 | $3,908,397 | dollars as filed | |
| UPSTREAM BIO INC | 91678A107 | COMMON STOCK | 300,361 | $1,582,902 | dollars as filed | |
| TCGX ACQUISITION CORP | G8708J109 | COM | 100,000 | $1,251,000 | dollars as filed | |
| Gossamer Bio, Inc. | 38341P201 | Common Stock, $0.0001 par value per share | 87,956 | $1,042,279 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001744967-26-000014 | this filing | 2026-11-16 |